Citius Oncology Inc reports results for the quarter ended June 30 - Earnings Summary

Citius Oncology

14/08/2026 22:08

Citius Oncology Inc CTOR.OQ reported a quarterly adjusted loss of 8 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The lone analyst forecast for the quarter was for a loss of 8 cents per share. 
Revenue was $1.49 million​; analysts expected $2.50 million. 
Citius Oncology Inc's reported EPS for the quarter was a loss of 8 cents​.
The company reported a quarterly loss of $8.92 million.
Citius Oncology Inc shares had risen by 27.2% this quarter and lost 17.3% so far this year.
FORECAST CHANGES
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Citius Oncology Inc is $4.00, about 79.3% above its last closing price of $0.83
This summary was machine generated from LSEG data August 14 at 09:08 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.08
-0.08
Met
Mar. 31 2026 
-0.01
-0.27
Missed
 
-0.06
Sep. 30 2025 
-0.12
-0.06
Beat